新股消息 | 癌症早期篩查公司諾輝健康計劃明年初在港上市，集資3億美元，奧博、禮來、啓明創投等入股
uSMART盈立智投11月11日消息，IFR報道，諾輝健康正尋求明年初在香港上市，籌集資金3億美元。這家專注於癌症早期篩查的公司週二（10日）提交了IPO申請，高盛和瑞銀是保薦人。
諾輝健康是中國結直腸癌篩查市場的先行者，專注於設計、開發癌症篩查測試及將其商業化。
目前有兩大用戶家居結直腸癌篩查測試產品——常衛清及噗噗管，已實現商業化，面向不同風險程度的目標人群。此外，公司還有有兩種胃癌及宮頸癌的癌症篩查後期候選產品。
根據弗若斯特沙利文，專有的非侵入性多靶點FIT-DNA測試－常衛清爲中國首個且唯一獲國家藥監局批准的分子癌症篩查測試。常衛清的目標客戶爲中國1.2億的結直腸癌高危人群，可讓用戶居家採集糞便樣本，避免具有侵入性的手術，同時取得較高測試靈敏度及特異性。
專有的非侵入性糞便FIT測試噗噗管爲中國首個獲國家藥監局批准的自檢FIT篩查產品。根據弗若斯特沙利文，就銷量及銷售收入而言，爲2019年中國最暢銷的自檢FIT結直腸癌篩查產品。噗噗管的目標客戶爲被建議進行結直腸癌篩查的中國大衆市場人群（於2019年有633百萬人），旨在普及結直腸癌篩查意識及識別高危人群。
根據弗若斯特沙利文，中國結直腸癌篩查市場由2015年的25億元增加至2019年的30億元，並預期將進一步增加至2030年的198億元，2019年至2030年的複合年增長率爲18.7%。另一方面，中國的結直腸癌篩查市場仍未大量開發，2019年篩查普及率僅爲16.4%，而美國則爲60.1%。
豪華投資陣容
自2015年成立以來，諾輝健康進行了多輪融資，最後一輪於今年7月完成，投後估值6.3億美元。投資者星光熠熠，包括
君聯資本，投資組合包括信達生物、藥明康德等
啓明創投，管理資產逾50億美元，投資組合包括小米、美團、啓明醫療等
禮來亞洲基金（LAV），領先的亞洲生命科學投資公司，投資組合涵蓋生物醫藥及醫療保健行業的所有主要領域，包括生物製藥、醫療器械、診斷及 醫療保健服務
Cormorant、奧博資本（OrbiMed），均爲知名醫藥類投資基金，投資了衆多港股明星醫藥IPO
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
